Literature DB >> 15361418

Using monoamine oxidase type B inhibitors in Parkinson's disease.

Yoav Ben-Shlomo, Kailash Bhatia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15361418      PMCID： PMC516644          DOI： 10.1136/bmj.329.7466.581

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

Review 1.  Treatment interventions for Parkinson's disease: an evidence based assessment.

Authors:  Olivier Rascol; Christopher Goetz; William Koller; Werner Poewe; Cristina Sampaio
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

Review 2.  MAO-B inhibitors for the treatment of Parkinson's disease.

Authors: 
Journal:  Mov Disord       Date:  2002       Impact factor: 10.338

3.  Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.

Authors:  Y Ben-Shlomo; A Churchyard; J Head; B Hurwitz; P Overstall; J Ockelford; A J Lees
Journal:  BMJ       Date:  1998-04-18

4.  Bias in meta-analysis detected by a simple, graphical test.

Authors:  M Egger; G Davey Smith; M Schneider; C Minder
Journal:  BMJ       Date:  1997-09-13

Review 5.  Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.

Authors:  Koon K Teo; Salim Yusuf; Marc Pfeffer; Christian Torp-Pedersen; Lars Kober; Alistair Hall; Janice Pogue; Roberto Latini; Rory Collins
Journal:  Lancet       Date:  2002-10-05       Impact factor: 79.321

6.  Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.

Authors: 
Journal:  Ann Neurol       Date:  1998-03       Impact factor: 10.422

7.  Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial.

Authors:  A J Lees; R Katzenschlager; J Head; Y Ben-Shlomo
Journal:  Neurology       Date:  2001-11-13       Impact factor: 9.910

8.  Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients.

Authors:  Natalie J Ives; Rebecca L Stowe; Joanna Marro; Carl Counsell; Angus Macleod; Carl E Clarke; Richard Gray; Keith Wheatley
Journal:  BMJ       Date:  2004-08-13

9.  Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.

Authors:  A J Lees
Journal:  BMJ       Date:  1995-12-16

10.  Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?

Authors:  Y Ben-Shlomo; M G Marmot
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-03       Impact factor: 10.154
  10 in total
  3 in total

Review 1.  Alternatives to levodopa in the initial treatment of early Parkinson's disease.

Authors:  Andrew Lees
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

2.  NLRP3 inflammasome and glia maturation factor coordinately regulate neuroinflammation and neuronal loss in MPTP mouse model of Parkinson's disease.

Authors:  Hayate Javed; Ramasamy Thangavel; Govindhasamy Pushpavathi Selvakumar; Iuliia Dubova; Noah Schwartz; Mohammad Ejaz Ahmed; Smita Zaheer; Duraisamy Kempuraj; Shankar Iyer; Asgar Zaheer; Mohammad Moshahid Khan
Journal:  Int Immunopharmacol       Date:  2020-04-04       Impact factor: 4.932

3.  Neuroprotective effect of curcuminoids against inflammation-mediated dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.

Authors:  Rudra P Ojha; Manisha Rastogi; B Parimala Devi; Aruna Agrawal; G P Dubey
Journal:  J Neuroimmune Pharmacol       Date:  2012-04-21       Impact factor: 4.147
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.